Population
341 daily-care patients with atrial fibrillation receiving dabigatran for stroke prevention
Design
Cohort
Authors
Loading...
Supports dabigatran in real-world AF; leaves open adherence strategies amid high non-bleeding discontinuations.
In a real-world registry, dabigatran demonstrated effectiveness and safety for stroke prevention in atrial fibrillation, though treatment discontinuation rates due to non-bleeding side effects were high.
Ebertz et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: